The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.
Hosted on MSN5m
FDA beats EMA to most approved new drugs in 2024On 15 January, the two agencies released respective lists of medicines approved last year. The FDA approved 50 novel drugs ...
Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...
Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older ...
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...
Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar ...
Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, ...
Chinese regulators have accepted Zai Lab's (NASDAQ:ZLAB) market application for the drug KarXT, also known as xanomeline and ...
Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...
AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...
The potential adjunctive schizophrenia therapies are Newron Pharmaceuticals’ evenamide, Neurocrine Biosciences’ Ingrezza, Boehringer’s iclepertin and Bristol Myers’ Cobenfy. “Should ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback